相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells
Heather K. Kroh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Binary Clostridium difficile toxin (CDT) - A virulence factor disturbing the cytoskeleton
Klaus Aktories et al.
ANAEROBE (2018)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Dale N. Gerding et al.
CLINICAL INFECTIOUS DISEASES (2018)
Understanding Clostridium difficile Colonization
Monique J. T. Crobach et al.
CLINICAL MICROBIOLOGY REVIEWS (2018)
Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies
Cristina Joao et al.
JOURNAL OF IMMUNOLOGY (2018)
Stimulated enrichment of Clostridium difficile specific IgA in mature cow's milk
Christiane Schmautz et al.
PLOS ONE (2018)
Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody
Traian Sulea et al.
SCIENTIFIC REPORTS (2018)
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent &ITClostridium difficile&IT Infection
Vimalanand S. Prabhu et al.
CLINICAL INFECTIOUS DISEASES (2018)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
M. H. Wilcox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models
Jing-Hui Tian et al.
VACCINE (2017)
Characterization of Chicken IgY Specific to Clostridium difficile R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Disease
Marjorie Pizarro-Guajardo et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
Melanie L. Hutton et al.
SCIENTIFIC REPORTS (2017)
Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration
O. H. Negm et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications
Russell G. A. Jones et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2016)
Single-domain antibodies for biomedical applications
Simon Krah et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies
Kasper Krogh Andersen et al.
INFECTION AND IMMUNITY (2016)
Immune responses induced by Clostridium difficile
Severine Pechine et al.
ANAEROBE (2016)
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection
Zhiyong Yang et al.
PATHOGENS AND DISEASE (2016)
Clostridium difficile infection
Wiep Klaas Smits et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease
Hiba Kandalaft et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2015)
Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model
Amin Reza Nikpoor et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT
Mandy Unger et al.
SCIENTIFIC REPORTS (2015)
Hyperimmune Bovine Colostrum as a Novel Therapy to Combat Clostridium difficile Infection
Jerlyn K. Sponseller et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
A Novel Multivalent, Single-Domain Antibody Targeting TcdA and TcdB Prevents Fulminant Clostridium difficile Infection in Mice
Zhiyong Yang et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Multistate Point- Prevalence Survey of Health Care- Associated Infections
Shelley S. Magill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intravenous Immunoglobulin in the Treatment of Severe Clostridium Difficile Colitis
Nihar Shah et al.
JOURNAL OF GLOBAL INFECTIOUS DISEASES (2014)
Hyperimmune bovine colostrum for treatment of GI infections A review and update on Clostridium difficile
Jennifer Steele et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Back to the future: recombinant polyclonal antibody therapeutics
Xian-zhe Wang et al.
CURRENT OPINION IN CHEMICAL ENGINEERING (2013)
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Oliver A. Comely et al.
CLINICAL INFECTIOUS DISEASES (2012)
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Israel Lowy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Alternative strategies for Clostridium difficile infection
Martijn P. Bauer et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Maja Rupnik et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Preparation and use of therapeutic antibodies primarily of human origin
E. Richard Stiehm et al.
BIOLOGICALS (2008)
Short- and long-term attributable costs of Clostridium difficile -: Associated disease in nonsurgical inpatients
Erik R. Dubberke et al.
CLINICAL INFECTIOUS DISEASES (2008)
A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial
Eero Mattila et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2008)
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
Claribel P. Taylor et al.
VACCINE (2008)
Clostridium difficile-associated diarrhoea:: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses
Sandra C. Numan et al.
GUT (2007)
The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile
Karen W. H. Young et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2007)
Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea
Paul Juang et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2007)
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters
Gregory J. Babcock et al.
INFECTION AND IMMUNITY (2006)
Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea
Stuart McPherson et al.
DISEASES OF THE COLON & RECTUM (2006)
Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile associated diarrhoea:: preclinical and preliminary clinical data
JT van Dissel et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2005)
Immunological properties of surface proteins of Clostridium difficile
S Péchiné et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2005)
Human antibody response to surface layer proteins in Clostridium difficile infection
D Drudy et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2004)
Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea
MH Wilcox
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea
ILP Beales
GUT (2002)
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
L Kyne et al.
LANCET (2001)
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
L Kyne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
